Drug deliveries have been revolutionized over time with the emergence of many carriers, such as liposomes (lipid bilayers), hydrogels (polymeric hydrophobic-active molecules), nanostructured molecules, biological polymers, and micelles. Each of the carriers has made an impact in the advancement of medicine and addresses the United Nations Sustainable Development Goal 3 (SDG-3), which focuses on human health and well-being. The challenges faced by these carriers, which include immune-system stimulation, material stability, carrier carrying capacity, potential toxicity, drug-carrier compatibility, biodistribution, and production shortfalls, have kept researchers on their toes for an alternate, friendly, and more efficient carrier. The setting of the micellar system in the front burner of the drug delivery scheme was after its first clinical trial (CT) in 2010 in Japan. Subsequently, many CT studies centring on the pharmacodynamics/kinetics of antitumour drug improvement with micelles have been underpinned. Paclitaxel-polyethylene glycol micelle encapsulation stands as a typical example. Others, such as Genexol-polymeric micelle, polyaspartate-polyethylene glycol, and polyglutamic acid-polyethylene glycol, have aimed to address the bioaccumulation and targeting of cell sites. Its polymeric form ushers in drug-loading capability, controllable drug release, and retention period in the field of modern medicine that stresses precision, less energy, and great impact. Many efforts have been made on the side of the researchers to harness, build, and reinforce this green and less toxic carrier as a new prototype of drug carrier by tuning the capabilities of both monomeric and polymeric micelles. The discussion around the micelle’s structure, stability, cell interactions, delivery system, challenges, and prospective route is not left out.